Every 10-Q that BORN INC (BRRN) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow BRRN and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full BRRN filings page.
BRYN Inc., a Nevada corporation with no current operating revenue, reported a net loss of $178,646 for the quarter and $209,583 for the six months ended June 30, 2026, driven entirely by administrative expenses.
Total assets were only $1,909 against liabilities of $206,170, resulting in a stockholders’ deficit of $204,260 and a working capital deficit of $212,910. Accumulated deficit reached $117,771,719. The company discloses substantial doubt about its ability to continue as a going concern and is relying on interest-free demand loans, including $139,037 from Medo Healthcare LLC, to fund operations.
On April 24, 2026, Medo Healthcare LLC bought 10,000,000 Series A Preferred shares for $175,000, obtained control, and installed new management. BRYN has 450,000,000 common shares outstanding and 10,000,000 Series A Preferred shares, each convertible into 250 common shares. Management plans to pivot into acquiring pharmaceutical distributors and applying AI-based technology, but this plan is at an early stage. Disclosure controls have multiple material weaknesses, including lack of an independent board, limited segregation of duties, and undocumented internal controls.
Bryn Inc. reports unaudited results for the three months ended March 31, 2026, as a non-operating shell company. The Company generated no revenue and recorded a net loss of $30,937, up from $16,410 a year earlier, driven entirely by administrative expenses.
At March 31, 2026 Bryn showed a working capital deficit of $34,264 and an accumulated deficit of $117,593,073, and its auditors highlight substantial doubt about its ability to continue as a going concern. Related parties provided $24,470 of interest-free demand loans, and $93,285 of related-party debt was settled through issuing 30,015,577 common shares, bringing total common shares outstanding to 450,000,000.
Control effectively shifted on April 24, 2026 when MEDO Healthcare LLC purchased 10,000,000 super-voting Series A-1 preferred shares for $175,000 and installed new leadership. The new owners plan to rebrand as MEDO Technologies, Inc. and pursue acquisitions of nationwide pharmaceutical distributors augmented by AI-based optimization, but this strategy remains at the planning stage.
Byrn Inc. (BRRN) filed its quarterly report for the period ended September 30, 2025, reporting no revenue and a net loss of $3,700 for the quarter and $28,582 for the nine months. The company states there is substantial doubt about its ability to continue as a going concern due to limited cash resources and ongoing losses.
Operations are inactive while management explores a potential reverse merger or similar transaction. Funding during the period came from interest‑free demand loans from a related party, with amounts due of $82,635 as of September 30, 2025. The company reported a working capital deficit of $85,168 and total liabilities of $85,168.
Management concluded that disclosure controls and internal control over financial reporting were not effective due to material weaknesses, including lack of segregation of duties and absence of an independent board or audit committee. Shares outstanding were 419,984,423 as of October 21, 2025.